Embla Medical – Presentation of Interim report Q3 2024

You can already now sign up for the event and send in your questions. You don’t have to participate live to submit questions for the event.

Embla Medical will release its Q3 2024 interim report on 22 October 2024. The company’s management will present the results in a virtual live event with a Q&A session the next day, 23 October 2024 at 12:30. Besides the financial results, you can get an update on the recent business and regulatory developments.

In Q2 2024, Embla Medical delivered its highest-ever quarterly sales and realized an organic growth of 6%. EBITDA margin came in at 22%, well above last year's margins of 19%. Due to the strong momentum and profitability recorded in the first half of 2024, the guidance for the full year 2024 has been narrowed to 6-8% organic growth (previously 5-8%), and the EBITDA margin before special items is narrowed to ~20% (previously 19-20%). The topline growth is expected to be driven by continued volume growth and a positive mix effect from functional trade-up to bionics. The comparable base for the second half is also lower. The 2024 margin improvement is driven by the cost reduction initiatives in manufacturing implemented during Q1 and benefits from positive product mix, scalability, and cost control in OPEX.

Embla Medical is a leading global provider of innovative mobility solutions in the medical technology space. Embla Medical improves people’s mobility through the delivery of Prosthetics, Bracing & Supports, and Patient Care. Headquartered in Iceland, the company employs over 4,000 people located across 36 countries worldwide. Embla Medical has extensive operations in the Americas, Europe, and Asia, as well as distributors in other markets.

Dislcaimer: HC Andersen Capital receives payment from Embla Medical for a Corporate Visibility/Digital IR subscription agreement. /Michael Friis, 10.02 24 September 2024.